Funded in part by Amarin Pharma
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies
Ballantyne CM, Bays HE, Philip S, Doyle RT, Braeckman RA, Stirtan WG, Soni PN, Juliano RA
Atherosclerosis · 39 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Government
- U.S. Food and Drug Administration
- Company
- Amarin Pharma
Based on 2 listed funder(s).
Publication
- Published
- 2016-08-23 · Atherosclerosis · vol. 253 · pp. 81–87
- Publisher
- Elsevier BV
- Cited
- 52 citations · more than 94% of similar papers · 4.4× the field average
- Impact
- Top 10% most cited in its field
- References
- 44 works
- Access
- Open access (hybrid journal) · CC-BY-NC-ND
- Research areas
- Fatty Acid Research and Health · Antioxidant Activity and Oxidative Stress · Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- Eicosapentaenoic acid, Triglyceride, Placebo, Internal medicine, Statin, Ethyl ester, Medicine, Cholesterol, Endocrinology, Fatty acid, Chemistry, Biochemistry, Polyunsaturated fatty acid, Pathology
- MeSH
- humans, cardiovascular diseases, hypertriglyceridemia, cholesterol, fatty acids, omega-3, eicosapentaenoic acid, triglycerides, lipoproteins, platelet aggregation inhibitors, hydroxymethylglutaryl-coa reductase inhibitors, data interpretation, statistical, double-blind method, adult, aged, middle aged, female, male, atherosclerosis, hypolipidemic agents
8 authors
From US
- Christie Mitchell Ballantyne · correspondingHouston Methodist; Baylor College of Medicine
- Harold Edward BaysLouisville Metabolic and Atherosclerosis Research Center
- Sephy PhilipAmarin (United States)
- Ralph T. DoyleAmarin (United States)
- Rene A. BraeckmanAmarin (United States)
- William G. StirtanAmarin (United States)
Abstract
Background and aims
Remnant-like particle cholesterol (RLP-C) is atherogenic and may increase atherosclerotic cardiovascular disease risk. Icosapent ethyl is a high-purity prescription eicosapentaenoic acid ethyl ester (approved as an adjunct to diet to reduce triglyceride [TG] levels in adult patients with TGs ≥500 mg/dL [≥5.65 mmol/L] at 4 g/day). In the MARINE and ANCHOR studies, icosapent ethyl reduced TG and other atherogenic lipid parameter levels without increasing low-density lipoprotein cholesterol (LDL-C) levels. This exploratory analysis evaluated the effects of icosapent ethyl on calculated and directly measured RLP-C.
Methods
MARINE (TGs ≥500 and ≤2000 mg/dL [≥5.65 mmol/L and ≤22.6 mmol/L]) and ANCHOR (TGs ≥200 and <500 mg/dL [≥2.26 and <5.65 mmol/L] despite statin-controlled LDL-C) were phase 3, 12-week, double-blind studies that randomized adult patients to icosapent ethyl 4 g/day, 2 g/day, or placebo. This analysis assessed median percent change from baseline to study end in directly measured (immunoseparation assay) RLP-C levels (MARINE, n = 218; ANCHOR, n = 252) and calculated RLP-C levels in the full populations.
Results
Icosapent ethyl 4 g/day significantly reduced directly measured RLP-C levels -29.8% (p = 0.004) in MARINE and -25.8% (p = 0.0001) in ANCHOR versus placebo, and also reduced directly measured RLP-C levels to a greater extent in subgroups with higher versus lower baseline TG levels, in patients receiving statins versus no statins (MARINE), and in patients receiving medium/higher-intensity versus lower-intensity statins (ANCHOR). Strong correlations were found between calculated and directly measured RLP-C for baseline, end-of-treatment, and percent change values in ANCHOR and MARINE (0.73-0.92; p < 0.0001 for all).
Conclusions
Icosapent ethyl 4 g/day significantly reduced calculated and directly measured RLP-C levels versus placebo in patients with elevated TG levels from the MARINE and ANCHOR studies.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-ND).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.